Tempus AI TEM has skyrocketed 21% in the last three days, fueled by news of a $200 million partnership with AstraZeneca AZN ...

Tempus AI has reported impressive growth, but some of the volatile quarterly numbers have chased off aggressive investors.

The partners plan to build evidence packages that standardize comprehensive genomic profiling and other molecular testing ...

Acquisitions Reinforce Clinical and Data Infrastructure: Tempus AI’s 2025 acquisitions of Deep 6 AI and Ambry Genetics have ...

Ambry was subsequently acquired by Tempus AI in February 2025 ... From 2016 to 2021, Aaron led Ambry Genetics as CEO and transformed the company into one of the largest hereditary cancer testing ...

Marcy Richardson from Ambry Genetics discusses the importance of a new study that assessed the functional impact of thousands of BRCA2 variants, identifying those that may increase cancer risk. What ...

Acquisitions Reinforce Clinical and Data Infrastructure: Tempus AI’s 2025 acquisitions of Deep 6 AI and Ambry Genetics have expanded its clinical footprint to more than 750 sites and 30 million ...